Suchergebnisse - "Fajgenbaum, David C."

PubPharm (7)

1

Transcriptome and unique cytokine microenvironment of Castleman disease

enthalten in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2022

von Wing, A. | Xu, J. | Meng, W. | +12

2

Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease

enthalten in: Blood advances | 2021

von Pierson, S. | Shenoy, S. | Oromendia, A. | +22

3

Increased mTOR activation in idiopathic multicentric Castleman disease

enthalten in: Blood | 2020

von Arenas, D. | Floess, K. | Kobrin, D. | +14

CommentIn: Blood. 2020 May 7;135(19):1614-1615. - PMID 32379877

4

Overview of Castleman disease

enthalten in: Blood | 2020

von Dispenzieri, A. | Fajgenbaum, D.

5

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease

enthalten in: The Journal of clinical investigation | 2019

von Fajgenbaum, D. | Langan, R. | Japp, A. | +20

CommentIn: J Clin Invest. 2019 Oct 1;129(10):4086-4088. - PMID 31524635

6

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease : secondary analyses of phase II clinical trial data

enthalten in: British journal of haematology | 2019

von Morra, D. | Pierson, S. | Shilling, D. | +6

7

Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease

enthalten in: American journal of hematology | 2018

von Pierson, S. | Stonestrom, A. | Shilling, D. | +8

1
[1]